R. Ross

发表

The Effect of Biologically Effective Dose and Radiation Treatment Schedule on Overall Survival in Stage I Non-Small Cell Lung Cancer Patients Treated With Stereotactic Body Radiation Therapy.

C. Gross, S. Evans, R. Decker, 2016, International journal of radiation oncology, biology, physics.

Mortality in men with localized prostate cancer treated with brachytherapy with or without neoadjuvant hormone therapy

A. D'Amico, Ming-Hui Chen, D. Dosoretz, 2010, Cancer.

Changes in prostate cancer presentation for radiation oncology care after USPSTF recommendations, 2007-2013.

C. Gross, S. Evans, R. Decker, 2015 .

Multi-institutional analysis of stereotactic body radiation therapy for operable early-stage non-small cell lung carcinoma.

C. Gross, R. Decker, B. Kann, 2019, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

Risk of death from prostate cancer after brachytherapy alone or with radiation, androgen suppression therapy, or both in men with high-risk disease.

A. D'Amico, Ming-Hui Chen, B. Moran, 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Patient-reported quality of life after stereotactic body radiation therapy versus moderate hypofractionation for clinically localized prostate cancer.

C. Gross, M. Ritter, E. Horwitz, 2016, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

Patterns of utilization and comparative efficacy of altered fractionation and concurrent chemoradiation for treatment for T2N0M0 glottic carcinoma

R. Selvaraj, A. Ahamad, R. Ross, 2019, Journal of Radiation Oncology.

Neoadjuvant hormonal therapy use and the risk of death in men with prostate cancer treated with brachytherapy who have no or at least a single risk factor for coronary artery disease.

A. D'Amico, Ming-Hui Chen, B. Moran, 2014, European urology.

Coronary revascularization and mortality in men with congestive heart failure or prior myocardial infarction who receive androgen deprivation

A. D'Amico, Ming-Hui Chen, S. Goldhaber, 2011, Cancer.

Androgen‐suppression therapy for prostate cancer and the risk of death in men with a history of myocardial infarction or stroke

A. D'Amico, Ming-Hui Chen, T. Choueiri, 2010, BJU international.

Total androgen blockade versus a luteinizing hormone-releasing hormone agonist alone in men with high-risk prostate cancer treated with radiotherapy.

A. D'Amico, Ming-Hui Chen, B. Moran, 2010, International journal of radiation oncology, biology, physics.

Identification of comorbidities that place men at highest risk of death from androgen deprivation therapy before brachytherapy for prostate cancer.

A. D'Amico, Ming-Hui Chen, Jim C Hu, 2013, Brachytherapy.

Routine bladder cancer treatment dictates divergence from trial-derived regimens: Results of treatment at 44 radiotherapy centers.

J. Efstathiou, A. Ahamad, R. Ross, 2018, Urologic oncology.

Predictors of prostate cancer-specific mortality in elderly men with intermediate-risk prostate cancer treated with brachytherapy with or without external beam radiation therapy.

A. D'Amico, Ming-Hui Chen, B. Moran, 2010, International journal of radiation oncology, biology, physics.

Radiation dose and cardiac risk in breast cancer treatment: An analysis of modern radiation therapy including community settings.

Julian C. Hong, Cary P Gross, Pamela R Soulos, 2017, Practical radiation oncology.

Increased Number of Beam Angles Is Associated With Higher Cardiac Dose in Adjuvant Fixed Gantry Intensity Modulated Radiation Therapy of Left-Sided Breast Cancer.

Julian C. Hong, C. Gross, S. Evans, 2017, International journal of radiation oncology, biology, physics.

Coronary artery revascularization and the risk of death in men with prostate cancer.

A. D'Amico, Ming-Hui Chen, S. Goldhaber, 2011, The Journal of urology.

The use of supplemental external beam radiotherapy in men with low-risk prostate cancer undergoing brachytherapy before and after the 1999 American Brachytherapy Society Guideline statement.

A. D'Amico, Ming-Hui Chen, B. Moran, 2010, Brachytherapy.

Stereotactic body radiotherapy with adjuvant systemic therapy for early-stage non-small cell lung carcinoma: A multi-institutional analysis.

C. Gross, R. Decker, B. Kann, 2019, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

Prostate cancer‐specific mortality and the extent of therapy in healthy elderly men with high‐risk prostate cancer

A. D'Amico, Ming-Hui Chen, B. Moran, 2010, Cancer.

Risk of all-cause and prostate cancer-specific mortality after brachytherapy in men with small prostate size.

A. D'Amico, P. Kantoff, Jim C Hu, 2011, International journal of radiation oncology, biology, physics.

Race and survival following brachytherapy-based treatment for men with localized or locally advanced adenocarcinoma of the prostate.

A. D'Amico, Ming-Hui Chen, D. Dosoretz, 2011, International journal of radiation oncology, biology, physics.

Race and survival following brachytherapy-based treatment for men with localized or locally advanced adenocarcinoma of the prostate.

A. D'Amico, D. Dosoretz, K. Winkfield, 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Androgen Deprivation Therapy Use in the Setting of High-dose Radiation Therapy and the Risk of Prostate Cancer-Specific Mortality Stratified by the Extent of Competing Mortality.

A. D'Amico, Ming-Hui Chen, B. Moran, 2016, International journal of radiation oncology, biology, physics.

Risk of death from prostate cancer after brachytherapy alone or with radiation, androgen suppression therapy, or both in men with high-risk disease.

A. D'Amico, Ming-Hui Chen, B. Moran, 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.